Executive Summary:
Since the passage of the Dietary Supplement Health and Education Act of 1994 (DSHEA), the U.S. Food and Drug Administration has demonstrated robust enforcement capabilities through diverse regulatory tools and strategic actions against potentially harmful and illegal products. This analysis examines FDA’s authorities and some noteworthy enforcement actions since DSHEA’s passage.
FDA’s Comprehensive Regulatory and Enforcement Arsenal:
FDA possesses extensive authority to enforce dietary supplement regulations through multiple complementary mechanisms:
Administrative Tools:
- FDA warning letters for violations of FDCA (Federal Food, Drug & Cosmetic Act) and associated regulations
- Administrative detention of suspect (adulterated or misbranded) products
- Mandatory recall authority for misbranded and adulterated food whose use is linked to reasonable probability of causing serious adverse health consequences or death
- Import alerts and border detention
- Identity/safety review of new dietary ingredient (NDI) notifications
- Review of structure/function claims
Judicial Enforcement (with DOJ cooperation):
- Seizures of products
- Permanent and preliminary injunctions
- Criminal prosecution
- Asset forfeiture and financial penalties
Market Surveillance:
- Adverse event monitoring system — FDA CAERS (Center for Food Safety and Applied Nutrition Adverse Event Reporting System) database.
- Product sampling and laboratory analysis
- Facility cGMP (current good manufacturing practices) inspections
- Post-market safety assessments
Historical Timeline of Major Enforcement Actions:
Foundation Building (2004-2012)
February 11, 2004 – Ephedrine alkaloids ban
FDA publishes a final rule banning supplements containing ephedrine alkaloids. The agency concluded these products are adulterated under federal law “because they present an unreasonable risk of illness or injury under the conditions of use recommended or suggested in labeling, or if no conditions of use are suggested or recommended in labeling, under ordinary conditions of use.” Prior to 2004, dietary supplements containing ephedrine alkaloids had been widely promoted for aiding weight control and improving sports performance and energy. FDA found ephedrine alkaloids had potentially dangerous effects on the heart and were linked to heart attack, stroke and death.
December 6, 2011 – Ephedrine enforcement
At FDA’s request, U.S. Marshals seize imported raw materials containing ephedrine alkaloids, removing more than $70,000 worth of these potentially dangerous dietary supplement ingredients from the market.
DMAA crackdown, OxyElite Pro (2012-2020)
April 24, 2012 – DMAA warning letters
FDA issues warning letters to sports nutrition brands selling DMAA (1,3-dimethylamylamine). FDA concludes DMAA-containing products are adulterated because DMAA is subject to a premarket, new dietary ingredient (NDI) notification that has not been submitted. FDA further maintains that synthetically produced DMAA does not meet the definition of a dietary ingredient in section 201(ff) of the Federal Food, Drug and Cosmetic Act. (See FDA’s “DMAA in products marketed as dietary supplements”).
June 2013 – USPlabs administrative detention
FDA administratively detains two DMAA-containing products, OxyElite Pro and Jack3d, after USPlabs initially refused FDA’s efforts to achieve voluntary compliance. The company ultimately destroys the detained products, estimated to have been worth more than $8 million at the retail level, and agrees to stop manufacturing supplements with DMAA.
November 2013 – Hi-Tech Pharmaceuticals seizure
FDA seizes DMAA-containing products from Hi-Tech Pharmaceuticals. A federal judge rules in 2017 that DMAA is not a dietary ingredient, and Hi-Tech’s DMAA-containing products are adulterated and subject to seizure. A federal appeals court later affirmed the judgment, and the U.S. Supreme Court in 2020 denied a request to hear the case.
November 6, 2013 – Liver injuries
FDA notifies USPlabs LLC about findings indicating a link between the use of certain OxyElite Pro products and a cluster of liver illnesses reported in Hawaii. Letter concludes there was a reasonable probability that OxyElite Pro dietary supplements are adulterated and use of, or exposure to, the dietary supplements would cause serious adverse health consequences or death to humans.
FDA alerts USPlabs that if it does not initiate a voluntary recall, the agency could by law order the company to immediately stop distributing the dietary supplements.
November 9, 2013 – OxyElite Pro recall
USPlabs recalls OxyElite Pro supplement products that were subject to the letter referenced above. Company subsequently expands recall to include another flavor of one of the products.
November 17, 2015 – USPlabs criminal indictment
An 11-count criminal indictment is unsealed against USPlabs, S.K. Laboratories Inc. and their executives related to the sale of supplement products. Among other charges, the indictment alleged USPlabs engaged in a conspiracy to import ingredients from China using false certificates of analysis and false labeling, then lied about the source and nature of those ingredients after it placed them in its products. The indictment also alleged the defendants sold some of their products without determining whether they would be safe to use.
October 2020 – USPlabs executives sentenced
A U.S. district court judge sentences the CEO of USPlabs, Jacobo Geissler, to 60 months in prison, and the president, Jonathan Doyle, to 24 months in prison. The company was previously sentenced to pay $4.7 million in criminal forfeiture, and SK Laboratories was ordered to forfeit $6 million in connection with the case.
Diversified Enforcement (2016-present)
January 2016 – Kratom administrative detention
FDA administratively detains kratom-containing supplement, based on authority to detain a food or supplement if it has reason to believe the product is misbranded or adulterated.
October 31, 2017 – SARMs warning campaign
FDA warns against the use of SARMs (selective androgen receptor modulators) in bodybuilding products, noting SARMs have not been approved by FDA and are associated with serious safety concerns, including life-threatening reactions like liver damage and the potential to increase the risk of heart attack or stroke. That same month, the agency sent warning letters to three companies for selling SARMs, warning that failure to correct the alleged violations may result in injunction and seizure.
February 16, 2021 – SARMs criminal prosecution
U.S. Department of Justice announces that sports supplement company was sentenced to about a year in prison after pleading guilty to introducing unapproved new drugs into interstate commerce. In pleading guilty, owner admitted that he and his company unlawfully distributed SARMs and other substances that FDA had not approved, including ostarine (MK-2866), ligandrol (LGD-4033) and testolone (RAD-140).
January 2024 – Yellow oleander safety crisis
FDA issues warning about certain supplements substituted with toxic yellow oleander. Then in March 2024, FDA discloses it continues to receive adverse event reports related to products identified in the safety alert. FDA reminds consumers to avoid toxic yellow oleander products because they can cause cardiovascular, gastrointestinal or neurologic adverse health effects that may be severe or fatal.
Conclusion:
This analysis demonstrates FDA’s robust enforcement toolkit and strategic evolution in protecting public health while supporting legitimate dietary supplement commerce. The agency’s multi-faceted approach combines administrative efficiency with judicial enforcement power to address both immediate safety threats and systemic compliance challenges.
Key Hyperlinks Preserved:
